CytomX Therapeutics Inc. CTMX
$2.93
▲ +1.01% 24H
About
CytomX Therapeutics Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. The company's proprietary PROBODY® therapeutic platform creates masked molecules that remain inactive in circulation and nor…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees69
TickerCTMX
Statistics
Market Cap$637.8M
Revenue (TTM)$76.2M
Net Income-$17.4M
Net Margin-22.8%
EPS$-0.15
P/E15.93
P/S18.25
P/B2.03
EV/EBITDA-4.78
ROE-34.3%
Dividend Yield—
Price$2.93
Data: Twelve Data · Revenue = mcap / P/S